Hepta Bio

Founded in 2022 and headquartered in California City, US, Hepta Bio, Inc focuses on developing liquid biopsy technology for metabolic dysfunction-associated steatohepatitis (MASH).Hepta specializes in developing a next-generation liquid biopsy platform specifically for metabolic dysfunction-associated steatohepatitis (MASH), targeting a significant gap in early diagnostics for this prevalent chronic disease affecting over 20 million Americans. The core offering involves a non-invasive blood test that analyzes epigenetic patterns in cell-free DNA to reveal liver biology, thereby providing clinicians with critical tissue-level insights. This innovative diagnostic tool is designed for routine clinical practice, allowing for early detection, treatment decision-making, and longitudinal monitoring of liver inflammation and fibrosis. Hepta's technology is particularly valuable for healthcare providers and clinicians across the United States, enabling them to identify at-risk patients more quickly and efficiently.Hepta's revenue model is primarily driven by its innovative liquid biopsy service, which is positioned as a diagnostic tool for healthcare providers. Transactions typically occur on a B2B basis, where clinical laboratories and healthcare institutions incorporate Hepta's blood-based testing services into their offerings to patients. The pricing structure is expected to reflect the advanced technology and insights provided, with healthcare providers paying for each test conducted, which can be integrated into standard patient care workflows. The product is designed to ensure accessibility and efficiency in diagnosing metabolic diseases, thereby facilitating earlier interventions. Hepta aims to design and launch new products targeting additional chronic diseases by 2026, while also looking to expand into international markets, particularly in Europe and Asia, in the next few years.

1. Seed

   Nov 5, 2025

   Amount

   $6.7M

   Investors

   Locked